Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities class action

Aardvark Therapeutics Securities Fraud Class Action

Analysis based on 176 articles · First reported Aug 14, 2026 · Last updated Sep 23, 2026

Sentiment
-60
Attention
4
Articles
176
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The revelations of safety concerns and the FDA clinical hold have severely impacted Aardvark's stock, which fell approximately 71.4% from its IPO price. The securities class actions add legal and financial uncertainty, potentially leading to significant settlement costs and further reputational damage for the company.

Biopharmaceuticals Legal Services

MiNK Therapeutics, a clinical-stage biopharmaceutical company, is facing multiple securities fraud class action lawsuits filed by several law firms on behalf of investors who purchased shares in its February 13, 2025 IPO or during the Class Period from February 13, 2025 to May 14, 2026. The lawsuits allege that the company and certain officers made false and misleading statements and failed to disclose that its lead drug candidate, ARD-101, was less safe than represented, leading to overstated clinical, regulatory, and commercial prospects. The alleged safety issues came to light on February 27, 2026, when Aardvark voluntarily paused its Phase 3 HERO trial due to reversible cardiac observations at above-target doses, causing its stock to plummet over 56%. On May 14, 2026, the United States — Food and Drug Administration placed a full clinical hold on the ARD-101 investigational new drug application, halting all ongoing studies, and the stock fell another 32.1%. The lawsuits seek damages for investors who suffered losses, with a lead plaintiff deadline of October 13, 2026. The case is filed in the United States District Court for the Southern District of California.

94 Hagens Berman filed lawsuit MiNK Therapeutics
94 Faruqi & Faruqi investigating claims MiNK Therapeutics
90 MiNK Therapeutics paused HERO trial
90 Levi & Korsinsky filed class action MiNK Therapeutics
90 Schall Brown & Schwartz LLP filed class action lawsuit MiNK Therapeutics
88 Rosen Law Firm filed class action MiNK Therapeutics
87 Rosen Law Firm filed class action lawsuit MiNK Therapeutics
87 Rosen Law Firm filed class action MiNK Therapeutics
87 Hagens Berman filed class action MiNK Therapeutics
87 MiNK Therapeutics faced securities fraud lawsuit
86 MiNK Therapeutics paused Phase 3 trial
+ 16 more actions View on Dashboard
stock
Aardvark is the defendant in multiple securities fraud class actions. Its stock collapsed after disclosing safety issues and receiving an FDA clinical hold, and it faces potential liability and reputational harm.
Importance 100.0 Sentiment -90.0
govactor
The FDA placed a full clinical hold on Aardvark's ARD-101 IND, halting all ongoing studies. This regulatory action was a key trigger for the stock decline and the subsequent lawsuits.
Importance 80.0 Sentiment 0.0
priv
Robbins LLP is a shareholder rights law firm that announced the class action and is seeking lead plaintiffs. The firm represents investors on a contingency basis and may recover fees if the case succeeds.
Importance 60.0 Sentiment 20.0
priv
Bronstein, Gewirtz & Grossman filed a class action lawsuit against Aardvark and is soliciting investors to join, representing them on a contingency fee basis.
Importance 60.0 Sentiment 0.0
priv
Hagens Berman filed a class action lawsuit and is investigating the allegations, encouraging affected investors to contact the firm before the lead plaintiff deadline.
Importance 60.0 Sentiment 0.0
priv
Rosen Law Firm filed a class action lawsuit on behalf of Aardvark investors and is encouraging them to seek lead plaintiff status.
Importance 50.0 Sentiment 0.0
priv
Glancy Prongay Wolke & Rotter filed a securities fraud lawsuit and is investigating Aardvark's possible violations of federal securities laws.
Importance 50.0 Sentiment 0.0
priv
Faruqi & Faruqi is investigating potential claims and reminding investors of the lead plaintiff deadline, representing investors in the securities class action.
Importance 50.0 Sentiment 0.0
priv
Levi & Korsinsky, through SueWallSt, filed a class action and is actively soliciting investors, highlighting the alleged misrepresentations in the IPO documents.
Importance 50.0 Sentiment 0.0
priv
The Law Offices of Frank R. Cruz filed a class action lawsuit and is representing investors who suffered losses in Aardvark securities.
Importance 40.0 Sentiment 0.0
govactor
The SEC is mentioned in the context of its whistleblower program, which may provide rewards to individuals providing information about Aardvark's alleged misconduct.
Importance 30.0 Sentiment 0.0
per
Aaron Dumas, Jr. is an attorney at Robbins LLP who is a contact for investors. His role is to assist investors in the class action.
Importance 20.0 Sentiment 10.0
per
Brian J. Robbins is the founding partner of Robbins LLP and is involved in the class action. His role is to represent investors and seek recovery.
Importance 20.0 Sentiment 10.0
per
Peretz Bronstein is the founding partner of Bronstein, Gewirtz & Grossman and is a contact for investors in the class action.
Importance 20.0 Sentiment 0.0
per
Reed Kathrein is the Hagens Berman partner leading the investigation into the allegations against Aardvark.
Importance 20.0 Sentiment 0.0
+ 6 more entities View on Dashboard
Robbins LLP co-counsel ↔ Bronstein, Gewirtz & Grossman, LLC Robbins LLP frequently collaborates with Bronstein, Gewirtz & Grossman, LLC as co-counsel or co-solicitor in numerous se
Robbins LLP competitor ↔ Rosen Law Firm Robbins LLP frequently competes with Rosen Law Firm for lead plaintiff appointments in investor rights class action laws
Robbins LLP co-counsel ↔ Glancy Prongay & Murray Robbins LLP frequently acts as co-counsel with Glancy Prongay & Murray in various securities class action lawsuits, repr
Robbins LLP co-counsel ↔ Faruqi & Faruqi Robbins LLP frequently acts as co-counsel with Faruqi & Faruqi in various securities class action lawsuits, jointly repr
+ 23 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.